Rossana Berardi

Research interests

Publications

• Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

  Journal of Clinical Oncology · 2022 · https://doi.org/10.1200/jco.22.01134

• Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

  The Lancet Oncology · 2022 · 10.1016/s1470-2045(21)00660-4

• Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

  Journal for ImmunoTherapy of Cancer · 2021 · 10.1136/jitc-2021-002421

• COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30314-4

• Benefits and Limitations of a Multidisciplinary Approach in Cancer Patient Management

  Cancer Management and Research · 2020 · 10.2147/cmar.s220976

• Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events

  European Journal of Cancer · 2020 · https://doi.org/10.1016/j.ejca.2019.12.031

• First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status

  European Journal of Cancer · 2020 · 10.1016/j.ejca.2020.02.023

• A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

  Journal for ImmunoTherapy of Cancer · 2019 · https://doi.org/10.1186/s40425-019-0527-y

• Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

  Clinical Lung Cancer · 2019 · 10.1016/j.cllc.2019.02.006

• Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

  The Oncologist · 2019 · 10.1634/theoncologist.2018-0618

• Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges

  Cancer Treatment Reviews · 2016 · 10.1016/j.ctrv.2016.06.002

• ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

  ESMO Open · 2016 · 10.1136/esmoopen-2016-000097

• Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges

  Cancer Treatment Reviews · 2016 · 10.1016/j.ctrv.2016.06.002

• ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

  ESMO Open · 2016 · 10.1136/esmoopen-2016-000097

• Metabolic phenotype of bladder cancer

  Cancer Treatment Reviews · 2016 · https://doi.org/10.1016/j.ctrv.2016.03.005

• Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib

  Oncotarget · 2016 · 10.18632/oncotarget.10515

• PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises

  Cancer Treatment Reviews · 2015 · 10.1016/j.ctrv.2014.12.013

• Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma

  Cancer Immunology Immunotherapy · 2013 · 10.1007/s00262-013-1487-6

• Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study

  Annals of Oncology · 2012 · 10.1093/annonc/mdr572

• Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study

  Annals of Oncology · 2012 · 10.1093/annonc/mdr572

• Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

  Annals of Oncology · 2008 · https://doi.org/10.1093/annonc/mdn637

• Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy

  Clinical Cancer Research · 2008 · 10.1158/1078-0432.ccr-07-5234

• Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial

  The Lancet Oncology · 2008 · https://doi.org/10.1016/s1470-2045(07)70383-2

• Nuclear Factor-kB Tumor Expression Predicts Response and Survival in Irinotecan-Refractory Metastatic Colorectal Cancer Treated With Cetuximab-Irinotecan Therapy

  Journal of Clinical Oncology · 2007 · 10.1200/jco.2007.11.5022

• Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients

  Annals of Oncology · 2007 · 10.1093/annonc/mdm284

• Nuclear Factor-kB Tumor Expression Predicts Response and Survival in Irinotecan-Refractory Metastatic Colorectal Cancer Treated With Cetuximab-Irinotecan Therapy

  Journal of Clinical Oncology · 2007 · 10.1200/jco.2007.11.5022

• Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients

  Annals of Oncology · 2007 · 10.1093/annonc/mdm284

• Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases

  Journal of Clinical Oncology · 2007 · https://doi.org/10.1200/jco.2007.11.8604

• Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)

  Annals of Oncology · 2006 · https://doi.org/10.1093/annonc/mdl459

• Epidermal Growth Factor Receptor (EGFR) Status in Primary Colorectal Tumors Does Not Correlate With EGFR Expression in Related Metastatic Sites: Implications for Treatment With EGFR-Targeted Monoclonal Antibodies

  Journal of Clinical Oncology · 2004 · https://doi.org/10.1200/jco.2004.00.117

Current projects

No projects listed.